Visit our website
New America Cypbersecurity Initiative
New America Cypbersecurity Initiative
MIT Technology Review
MIT Technology Review
io9
io9
Techdirt
Techdirt
Knowledge@Wharton
Knowledge@Wharton
Bioscience Technology
Bioscience Technology
redOrbit
redOrbit
Technology & Marketing Law Blog
Technology & Marketing Law Blog
Popular Science Blog
Popular Science Blog
Pew Research Center
Pew Research Center
Genomics Law Report
Genomics Law Report
Science 2.0
Science 2.0
The Guardian Headquarters
The Guardian Headquarters
Genetic Literacy Project
Genetic Literacy Project
Disclaimer

Statements posted on this blog represent the views of individual authors and do not necessarily represent the views of the Center for Law Science & Innovation (which does not take positions on policy issues) or of the Sandra Day O'Connor College of Law or Arizona State University.

Prof. Betsy Grey Talks CTE and Aaron Hernandez Suit

The autopsy of late NFL star Aaron Hernandez revealed a severe form of chronic traumatic encephalopathy (CTE). Hernandez’s daughter recently sued the National Football League and the New England Patriots (Hernandez v. Nat’l Football League) for negligence related to her father’s CTE and subsequent suicide.

Bloomberg BNA’s Product Safety & Liability Reporter (subscription required) interviewed Professor Betsy Grey regarding some of the challenges faced by the plaintiffs in the Hernandez suit – primarily the problem of proving causation.

“Most athletes who have suffered concussions go on to live normal, apparently healthy lives,” said Grey. “So, it’s not clear why some individuals develop CTE and others do not. Repeated head trauma seems to be a key risk factor, but we’re not sure what the other factors are.”

Professor Grey, a Center for Law, Science & Innovation Faculty Fellow with a focus in neuroscience, also noted that the science of CTE is advancing. A test for CTE in living patients may be on the horizon.

“If a biomarker for diagnosing CTE is discovered—as the recent journal article by researchers from [BU’s School of Medicine] suggests—that may be
a game-changer […],” said Grey. “But we are a long way from using these early biomarkers for diagnostic purposes in clinical patients.”